Neuroendocrine prostate cancer could be restored to a state that responds to treatment
It may be possible to restore drug-resistant neuroendocrine prostate cancer to a state that responds to treatment by depletion of a certain protein in cancer cells. A recent study by the University of Eastern Finland found that this protein, DPYSL5, is expressed in neuroendocrine prostate cancer. Prostate cancer is the most common cancer in men, and the second most common cause of cancer death in Western countries. The growth of prostate cancer often depends on androgens, and the effect of androgens is sought to be reduced by drug therapy, especially in metastatic prostate cancer.